# Institute for Pharmacovigilance in Psychiatry, AMSP e.V.

**First published:** 08/02/2010

**Last updated:** 11/04/2023

Institution

Hospital/Clinic/Other health care facility

## Institution identification

nstitution ID	
46817	
nstitution countries	
Germany	
Гуре of institution	
Hospital/Clinic/Other health care facility	
nstitution website	
nttps://www.amsp.de	

#### **ENCePP** partner

Yes

## Institution description

The AMSP-Institute for Pharmacovigilance in Psychiatry (Arzneimittelsicherheit in der Psychiatrie) is a drug safety program. It assesses severe adverse reactions to all marketed psychotropic drugs in the naturalistic setting of routine clinical treatment of psychiatric inpatients. For AMSP purposes, psychotropic drugs also include neurologic drugs such as anticonvulsants and antiparkinson drugs. > 100 psychiatric hospitals in Germany, Switzerland and Austria have participated in the program from 1993 up to now. Physicians working in the hospitals systematically record severe adverse events, i.e. those that are (potentially) life-threatening or seriously endanger the patient's health, or considerably impair everyday functioning, or require the patient's transfer to another department or ward providing more intensive care. The ongoing project started in 1993.

### Institution details

Experience with collecting data directly from individual patients or respondents:

Yes

Interest in carrying out research that is funded by pharmaceutical companies:

Yes

#### Contact

Stefan Bleich bleich.stefan@mh-hannover.de



bleich.stefan@mh-hannover.de

Eckart Ruether eruethe@gwdg.de



eruethe@gwdg.de